Lyra Therapeutics (LYRA) Expected to Release Quarterly Earnings on Tuesday

Lyra Therapeutics (NASDAQ:LYRA) is projected to release its Q1 2026 resultson Tuesday, August 11th. Analysts expect the company to announce earnings of ($1.54) per share and revenue of $0.10 million for the quarter. Parties are encouraged to explore the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, July 29, 2026 at 4:00 PM ET.

Lyra Therapeutics Stock Performance

Shares of NASDAQ:LYRA opened at $0.34 on Monday. Lyra Therapeutics has a 52 week low of $0.00 and a 52 week high of $8.75. The firm has a market cap of $603,500.00, a PE ratio of -0.01 and a beta of 0.72. The firm’s fifty day moving average is $0.58 and its 200-day moving average is $0.87.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE grew its position in shares of Lyra Therapeutics by 33.7% in the 2nd quarter. Bank of America Corp DE now owns 28,542 shares of the company’s stock valued at $256,000 after buying an additional 7,190 shares during the last quarter. Citadel Advisors LLC bought a new position in shares of Lyra Therapeutics during the third quarter worth about $128,000. Finally, DRW Securities LLC acquired a new position in shares of Lyra Therapeutics in the fourth quarter worth approximately $52,000. 95.62% of the stock is owned by institutional investors and hedge funds.

About Lyra Therapeutics

Lyra Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing targeted drug delivery therapies for diseases of the ear, nose and throat (ENT). Leveraging its proprietary Therapeutic Drug Delivery (TDD) platform, the company designs bioresorbable, steroid-eluting implants that provide sustained, localized release of medication directly to affected tissue. This approach aims to improve patient outcomes by reducing the need for repeated administration and minimizing systemic side effects.

The company’s lead product candidate, LYR-210, is an implantable matrix that delivers the corticosteroid mometasone furoate over several months to treat chronic rhinosinusitis (CRS).